MRK - AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin
2024-05-29 11:50:26 ET
More on AstraZeneca
- AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
- AstraZeneca: A Triple Shot Of Income, Growth, And Value
- AstraZeneca: Strong In A Weak Market
- AstraZeneca, Daiichi Sankyo ADC misses key endpoint in phase 3 lung cancer trial
- Nona Biosciences and AstraZeneca sign global license and option agreement